Physician profile
Chris Kolyvas
NPI 1932157302
$1,965.93
in general payments reported to CMS, 2019-2025
26 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $614 · 2021: $238 · 2022: $330 · 2023: $217 · 2024: $147 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $489.84 | 2020 | |
| Merck Sharp & Dohme LLC | $172.08 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $149.75 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $136.85 | 2019-2023 | |
| Abiomed | $134.77 | 2020-2025 | |
| Abbott Laboratories | $129.34 | 2020-2025 | Cardiomems, Esprit, Perclose Prostyle |
| Novo Nordisk INC | $102.96 | 2021-2025 | Wegovy |
| Pfizer INC. | $92.67 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.31 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $55.24 | 2019-2022 | |
| Philips North America LLC | $51.98 | 2022 | |
| Amarin Pharma, INC. | $45.90 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.54 | 2020-2024 | Camzyos |
| Medtronic Vascular, INC. | $36.95 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $27.56 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $26.82 | 2023 | Onpattro |
| Heartflow, INC. | $24.05 | 2025 | |
| Kestra Medical Technology Services, INC. | $23.88 | 2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $23.88 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $21.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.03 | 2024 | Jardiance |
| W. L. Gore & Associates, INC. | $17.25 | 2022 | |
| Verity Pharmaceuticals INC. | $15.98 | 2023 | Trelstar |
| Chiesi USA, INC. | $15.73 | 2022 | |
| Boston Scientific Corporation | $13.57 | 2021 | |
| Biotronik INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Kolyvas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.